StockData

Ironwood Pharmaceuticals vs Mirum Pharmaceuticals

IRWD and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRWD and MIRM compare

Mirum Pharmaceuticals is the larger company, worth 7.4 times as much as Ironwood Pharmaceuticals ($6.0B against $801M).

Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 26.2% for Ironwood Pharmaceuticals).

Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −139% at Mirum Pharmaceuticals.

Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRWDMIRM
Size and price
Market cap$801M$6.0B
Share price$4.85$91.95
Change, 1 year43.9%28.7%
Change, 5 years−56.5%586%
Beta (5Y)1.050.61
Employees100372
StockData Score
Total score12 (better)5
Valuation score6 (better)0
Growth score23 (better)
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/E6.3×–
P/S2.1× (better)9.7×
EV/EBITDA3.1×–
FCF yield–−3.8%
Fair value$12.87–
Margin of safety62.3%–
Growth
Revenue growth (TTM)26.2%44.0% (better)
Revenue growth, 5Y average−5.3%–
EPS growth, 5Y average−25.6%–
Profitability
Operating margin60.1% (better)−135%
Net margin33.4% (better)−139%
FCF margin–−37.0%
Return on equity–−703%
Financial health
Interest coverage7.2× (better)−62.1×
Current ratio6.06 (better)2.86
Altman Z-score−1.91−0.22 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.2%110%
Held by insiders16.0%9.2%
Insider net buying, 12 months−$22.6M (better)−$32.8M
Short interest, % of float10.7%11.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.